.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Mallinckrodt
Boehringer Ingelheim
Dow
Argus Health
Farmers Insurance
Medtronic
Teva
US Department of Justice
Fuji

Generated: November 19, 2017

DrugPatentWatch Database Preview

Details for Patent: 6,987,108

« Back to Dashboard

Which drugs does patent 6,987,108 protect, and when does it expire?


Patent 6,987,108 protects TEMODAR and is included in one NDA. There has been one Paragraph IV challenge on Temodar.

This patent has thirty-two patent family members in twenty-three countries.

Summary for Patent: 6,987,108

Title:Pharmaceutical formulations of antineoplastic agents and processes of making and using the same
Abstract:In its several embodiments, this invention discloses a pharmaceutical formulation comprising at least one antineoplastic agent or a pharmaceutically acceptable salt thereof, and at least one dissolution enhancing agent sufficient to substantially dissolve said at least one antineoplastic agent in at least one aqueous diluent, wherein said dissolution enhancing agent is urea, L-histidine, L-threonine, L-asparagine, L-serine, L-glutamine or mixtures thereof; a lyophilized powder comprising said pharmaceutical formulation, and articles of manufacture thereof.
Inventor(s): Ugwu; Sydney (Wheeling, IL), Radhakrishnan; Vinay (Laurence Harbor, NJ), Ihnat; Peter M. (Brooklyn, NY), Witchey-Lakshmanan; Leonore C. (Piscataway, NJ)
Assignee: Schering Corporation (Kenilworth, NJ)
Application Number:10/371,808
Patent Claim Types:
see list of patent claims
Formulation; Compound; Composition;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Merck Sharp Dohme
TEMODAR
temozolomide
POWDER;INTRAVENOUS022277-001Feb 27, 2009RXYesYes► Subscribe► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 6,987,108

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,674,790Processes of making and using pharmaceutical formulations of antineoplastic agents► Subscribe
8,623,868Processes of making and using pharmaceutical formulations of antineoplastic agents► Subscribe
8,076,335Processes of making pharmaceutical formulations of antineoplastic agents► Subscribe
7,786,118Pharmaceutical formulations of antineoplastic agents► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 6,987,108

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Slovenia1478339► Subscribe
Singapore161101► Subscribe
Portugal1478339► Subscribe
Poland205936► Subscribe
Poland372319► Subscribe
New Zealand534378► Subscribe
Norway335045► Subscribe
Norway20043961► Subscribe
MexicoPA04008133► Subscribe
South Korea100970528► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Cantor Fitzgerald
Healthtrust
Fish and Richardson
Johnson and Johnson
AstraZeneca
Colorcon
Merck
Farmers Insurance
Baxter
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot